BIO Stock Forecast 2025-2026
Distance to BIO Price Targets
BIO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Bio-Rad (BIO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BIO and similar high-potential opportunities.
Latest BIO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BIO has a bullish consensus with a median price target of $377.50 (ranging from $270.00 to $409.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $238.18, the median forecast implies a 58.5% upside. This outlook is supported by 4 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 13.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO Analyst Ratings
BIO Price Target Range
Latest BIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $270.00 |
| Feb 12, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $345.00 |
| Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
| Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
| Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
| Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
| Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
| Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
| Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
| Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 | |
| May 8, 2024 | UBS | Dan Leonard | Buy | Maintains | $385.00 |
| Apr 3, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $365.00 |
| Feb 16, 2024 | UBS | Dan Leonard | Buy | Maintains | $420.00 |
| Feb 16, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $480.00 |
| Dec 7, 2023 | UBS | Dan Leonard | Buy | Initiates | $395.00 |
| Aug 7, 2023 | Wells Fargo | Dan Leonard | Overweight | Maintains | $525.00 |
| Aug 4, 2023 | Credit Suisse | Dan Leonard | Outperform | Maintains | $550.00 |
| Aug 4, 2023 | RBC Capital | Conor McNamara | Outperform | Maintains | $524.00 |
Bio-Rad Laboratories Inc. (BIO) Competitors
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories Inc. (BIO) Financial Data
Bio-Rad Laboratories Inc. has a market capitalization of $6.69B with a P/E ratio of -3.6x. The company generates $2.57B in trailing twelve-month revenue with a -71.9% profit margin.
Revenue growth is -2.0% quarter-over-quarter, while maintaining an operating margin of +8.7% and return on equity of -24.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Bio-Rad Laboratories Inc. (BIO) Business Model
About Bio-Rad Laboratories Inc.
Manufactures life science research and diagnostic products.
Bio-Rad Laboratories generates revenue by providing a diverse array of life science research products and clinical diagnostics systems. The company sells reagents, instruments, and software that are essential for various scientific techniques, as well as solutions for disease identification and diagnosis in clinical settings.
Founded in 1952 and headquartered in Hercules, California, Bio-Rad is instrumental in advancing healthcare and medical research. Its contributions support significant improvements in diagnostic procedures and research methodologies, making it a vital player in the global health sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,700
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1980
Website
www.bio-rad.comBio-Rad Laboratories Inc. (BIO) Latest News & Analysis
Biosciences (BIO) is gaining investor interest, bolstered by strong performance in its ddPCR platform.
BIO's strong performance in the ddPCR platform signals growth potential, which could lead to increased investor confidence and possibly higher stock valuations.
Oncocyte Corp. announced progress on a regulated organ transplant rejection monitoring test kit, expected to launch next year, alongside its fourth quarter results.
Oncocyte's progress in launching a regulated organ transplant rejection test could drive revenue growth and enhance market position, influencing stock performance positively.
Bio-Rad's international revenue performance is under review, impacting Wall Street analysts' predictions and the stock's future prospects.
Bio-Rad's international revenue performance directly influences analyst predictions and stock prospects, impacting investor sentiment and potential stock price movements.
Bio-Rad has proposed to acquire Stilla Technology to enhance its digital PCR portfolio.
The acquisition could enhance Bio-Rad's product offerings in digital PCR, potentially boosting revenue and market share, which may positively impact stock performance.
Bio-Rad Laboratories, Inc. (NYSE:BIO) will hold its Q4 2024 earnings conference call on February 13, 2025, at 5:00 PM ET, featuring key executives and analysts from major firms.
The Q4 2024 earnings call provides insights into Bio-Rad's financial performance and strategic direction, influencing market sentiment and investment decisions.
Bio-Rad Laboratories announced a binding offer to acquire Stilla Technologies. The deal is pending employee consultations and regulatory approvals, expected to close by Q3 2023.
Bio-Rad's acquisition of Stilla Technologies could enhance its product offerings and market position, potentially driving growth and impacting stock performance.
Frequently Asked Questions About BIO Stock
What is Bio-Rad Laboratories Inc.'s (BIO) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Bio-Rad Laboratories Inc. (BIO) has a median price target of $377.50. The highest price target is $409.00 and the lowest is $270.00.
Is BIO stock a good investment in 2025?
According to current analyst ratings, BIO has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $238.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIO stock?
Wall Street analysts predict BIO stock could reach $377.50 in the next 12 months. This represents a 58.5% increase from the current price of $238.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bio-Rad Laboratories Inc.'s business model?
Bio-Rad Laboratories generates revenue by providing a diverse array of life science research products and clinical diagnostics systems. The company sells reagents, instruments, and software that are essential for various scientific techniques, as well as solutions for disease identification and diagnosis in clinical settings.
What is the highest forecasted price for BIO Bio-Rad Laboratories Inc.?
The highest price target for BIO is $409.00 from at , which represents a 71.7% increase from the current price of $238.18.
What is the lowest forecasted price for BIO Bio-Rad Laboratories Inc.?
The lowest price target for BIO is $270.00 from Brandon Couillard at Wells Fargo, which represents a 13.4% increase from the current price of $238.18.
What is the overall BIO consensus from analysts for Bio-Rad Laboratories Inc.?
The overall analyst consensus for BIO is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $377.50.
How accurate are BIO stock price projections?
Stock price projections, including those for Bio-Rad Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.